Variation in Medicaid and commercial coverage of cell and gene therapies

Growth in the availability of cell and gene therapies (CGTs) promises significant innovation in the treatment of serious diseases, but the high cost and one-time administration of CGTs has also raised concern about strain on health plan budgets and inequity in access. We used coverage information fr...

Full description

Bibliographic Details
Main Authors: Molly T. Beinfeld, Julia A. Rucker, Nola B. Jenkins, Lucas A. de Breed, James D. Chambers
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Health Policy Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2590229623000151